immunotherapy
AstraZeneca’s immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer.
n advisory panel on Wednesday unanimously urged the US Food and Drug Administration to approve a cutting-edge cancer therapy that genetically alters a patient's .
